Market Place
Sourcing Support
RenovoRx Begins Enrollment in Phase III TIGeR-PaC Pancreatic Trial
11 Dec 2024 //
GLOBENEWSWIRE
RenovoRx CEO to Host Investor Fireside Chat on December 17th
10 Dec 2024 //
GLOBENEWSWIRE
RenovoRx Receives First Orders for FDA-Cleared RenovoCath
05 Dec 2024 //
GLOBENEWSWIRE
Northwell Health Enrolls Patients In RenovoRx’s TIGeR-PaC Trial
20 Nov 2024 //
GLOBENEWSWIRE
RenovoRx Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
RenovoRx Increases RenovoCath Production Due To Demand
25 Sep 2024 //
GLOBENEWSWIRE
RenovoRx Announces Presentation On TAMP™ For Pancreatic Cancer
19 Sep 2024 //
GLOBENEWSWIRE
RenovoRx CEO To Present At H.C. Wainwright Investment Conference
27 Aug 2024 //
GLOBENEWSWIRE
RenovoRx Enrolls First Patient In Phase III TIGeR-PaC Trial At Nebraska Medical
14 Aug 2024 //
GLOBENEWSWIRE
RenovoRx Publishes Positive Early-Stage Data In The Oncologist®
31 Jul 2024 //
GLOBENEWSWIRE
RenovoRx Announces Publication Acceptance In The Oncologist
08 Jul 2024 //
GLOBENEWSWIRE
University of Nebraska Launches Patient Enrollment for RenovoRx’s Phase III
26 Jun 2024 //
GLOBENEWSWIRE
RenovoRx Appoints Ryan Witt As Head Of Strategy And Partnerships
10 Jun 2024 //
GLOBENEWSWIRE
RenovoRx CEO Issues Update Letter to Shareholders
30 May 2024 //
BUSINESSWIRE
Pre-Clinical Data Supports RenovoRx`s Targeted Cancer Delivery Platform
21 May 2024 //
BUSINESSWIRE
RenovoRx To Participate In A.G.P. Virtual Healthcare Showcase
14 May 2024 //
BUSINESSWIRE
RenovoRx CEO To Present At Aegis Capital Virtual Conference
02 May 2024 //
BUSINESSWIRE
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
18 Apr 2024 //
BUSINESSWIRE
RenovoRx: SIR Annual Meeting Clinical Data Abstract
16 Apr 2024 //
BUSINESSWIRE
RenovoRx $11.1M Placement Extends Runway To 2026
15 Apr 2024 //
BUSINESSWIRE
RenovoRx Announces $11.1 Million at Market Private Placement
08 Apr 2024 //
BUSINESSWIRE
RenovoRx to Present at the Canaccord Genuity Horizons in Virtual Conference
05 Apr 2024 //
BUSINESSWIRE
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
12 Mar 2024 //
BUSINESSWIRE
RenovoRx CEO Issues Letter to Shareholders
06 Feb 2024 //
BUSINESSWIRE
RenovoRx Closes $6.1 Million Private Placement
29 Jan 2024 //
BUSINESSWIRE
RenovoRx Engages OU Health as First Site in Preparation for PIII CouGar Trial
21 Dec 2023 //
BUSINESSWIRE
RenovoRx Announces Clinical Data Abstract at the 2024 Annual Scientific Meeting
19 Dec 2023 //
BUSINESSWIRE
RenovoRx Files New International Patent for Oncology Therapy Platform
13 Dec 2023 //
BUSINESSWIRE
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
14 Nov 2023 //
BUSINESSWIRE
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference
02 Oct 2023 //
BUSINESSWIRE
RenovoRx Reports Second Quarter 2023 Financial Results
17 Aug 2023 //
BUSINESSWIRE
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
31 Jul 2023 //
BUSINESSWIRE
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy
20 Jul 2023 //
BUSINESSWIRE
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
20 Jun 2023 //
BUSINESSWIRE
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
12 Jun 2023 //
BUSINESSWIRE
RenovoRx Initiates Patient Enrollment for Pivotal Phase III TIGeR-PaC Trial
01 Jun 2023 //
BUSINESSWIRE
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO
25 May 2023 //
BUSINESSWIRE
RenovoRx to Present at the LD Micro Invitational XIII Conference
24 May 2023 //
BUSINESSWIRE
RenovoRx Reports 1Q 2023 FYR Results and Operational Highlights
15 May 2023 //
BUSINESSWIRE
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
28 Apr 2023 //
BUSINESSWIRE
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough
27 Apr 2023 //
BUSINESSWIRE
RenovoRx Presenting Phase III Trial Interim Analysis Data of the TIGeR-PaC Study
14 Apr 2023 //
BUSINESSWIRE
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
11 Apr 2023 //
BUSINESSWIRE
RenovoRx Announces Positive New Data from PIII Trial Interim Analysis
30 Mar 2023 //
BUSINESSWIRE
RenovoRx, Inc. Announces $5 Million Registered Direct Offering
30 Mar 2023 //
BUSINESSWIRE
RenovoRx PIII Open Label TIGeR-PaC Interim Analysis Shows Promising Data
08 Mar 2023 //
BUSINESSWIRE
RenovoRx Reports Full Year 2022 Financial Results
02 Mar 2023 //
BUSINESSWIRE
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
01 Mar 2023 //
BUSINESSWIRE
RenovoRx to Present at the Sequire Bio Virtual Conference on February 2, 2023
25 Jan 2023 //
BUSINESSWIRE
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy
18 Jan 2023 //
BUSINESSWIRE
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
05 Jan 2023 //
BUSINESSWIRE
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at ASCO GI
15 Dec 2022 //
BUSINESSWIRE
RenovoRx to Present at AIMsymposium Highlighting RenovoTAMP Therapy Platform
17 Nov 2022 //
BUSINESSWIRE
RenovoRx Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022
21 Oct 2022 //
BUSINESSWIRE
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
04 Oct 2022 //
BUSINESSWIRE
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
19 Sep 2022 //
BUSINESSWIRE
RenovoRx to Participate in the H.C. Wainwright Global Investment Conference
07 Sep 2022 //
BUSINESSWIRE
RenovoRx Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
RenovoRx Appoints James Ahlers as Chief Financial Officer
19 Jul 2022 //
BUSINESSWIRE
